Independent pharmacies have been closing at a rate of roughly one per day for years, and a big reason is simple: the businesses that decide how much a pharmacy gets paid for a prescription are the same businesses that decide how much a pharmacy's competitors get paid. On July 14, 2026, the Federal Trade Commission announced it had settled its antitrust case against Caremark, CVS Health's pharmacy benefit manager (PBM), over practices the agency says artificially inflated insulin list prices and squeezed independent drugstores. It's the second such settlement this year, following a February 2026 deal with Express Scripts (ESI), and it changes the financial playbook for any pharmacy that fills prescriptions through a Caremark-managed plan.
If you own or manage an independent pharmacy, this isn't just industry news — it's a set of new choices about how your revenue gets calculated, when you get paid, and how predictable your margins can be. Here's what the settlement actually requires, and how to think about it from a bookkeeping and cash-flow perspective.
Why PBMs Matter to Your Bottom Line
Pharmacy benefit managers sit between drug manufacturers, insurance plans, and the pharmacy counter. They negotiate rebates with manufacturers, set the reimbursement rates pharmacies receive, and often own competing mail-order and specialty pharmacies. The FTC's own staff report on PBMs, along with years of complaints from independent pharmacy owners, describes a business model where the PBM can pay itself more favorably than it pays unaffiliated pharmacies for filling the exact same prescription.
The financial effects show up directly on an independent pharmacy's books:
- Reimbursement below acquisition cost. Multiple pharmacy owners have reported being paid less — sometimes by $100 or more per fill — than what they paid a wholesaler for the drug in the first place. That's a negative gross margin on the transaction before you've paid a single hour of staff time.
- Unpredictable DIR-style clawbacks. Direct and indirect remuneration fees, assessed after the sale, can retroactively erase margin on prescriptions you already dispensed and already recorded as revenue.
- Delayed and opaque payment cycles. When reimbursement methodology isn't transparent, forecasting cash flow — knowing what a given prescription will actually net you — becomes guesswork.
Layer those three together and it's easy to see why NCPA data shows roughly 8,600 retail pharmacy locations, chains and independents combined, have closed since 2017 — about 13.5% of the total. The closures aren't evenly distributed either: pharmacies in majority-Black and Latinx neighborhoods closed at rates nearly 10 percentage points higher than those in majority-white neighborhoods in 2024, according to reporting on the crisis, turning a margin problem into a healthcare-access problem.
What the Caremark Settlement Actually Changes
The FTC's order requires Caremark to adopt six operational reforms. The ones that matter most for a pharmacy's finance function:
1. A cost-plus reimbursement option
Caremark must offer retail community pharmacies an alternative reimbursement model based on acquisition cost plus a dispensing fee, rather than a rate tied to opaque, rebate-influenced list pricing. For a pharmacy, this is the headline change: instead of reverse-engineering whether a given NDC will be profitable under a spread-pricing contract, you get a formula you can actually model — cost of the drug, plus a defined fee, minus nothing you can't see coming.
2. Point-of-sale rebate pass-through
Caremark must offer plan sponsors a standard option that passes manufacturer rebates through to patients at the point of sale, rather than basing patient cost-sharing on list price. The FTC estimates this could unlock up to $4.5 billion in additional patient savings over the next decade, on top of $8.5 billion in savings the settlement locks in elsewhere. For pharmacies, rebate pass-through reduces the friction of patients walking away from the counter over sticker shock on a drug that Caremark itself is receiving a rebate on.
3. Delinked PBM compensation
The order decouples Caremark's own fees from drug list prices, removing the built-in incentive to steer plans and patients toward higher-priced drugs because a higher list price means a bigger PBM cut.
4. Hub pharmacy protections
Caremark is barred from unfairly interfering with a network pharmacy's ability to work with hub pharmacy service providers — the intermediaries that help identify lower-cost drug options and coordinate manufacturer financial assistance for patients. An independent monitor will review complaints about interference.
5. An end to rebate-guarantee lock-in
Plan sponsors get alternatives to all-or-nothing rebate guarantee contracts, which historically gave PBMs leverage to resist formulary changes that would have helped patients or competing pharmacies.
6. Expanded transparency into contracting practices
Caremark has broader disclosure obligations around its financial arrangements, which — over time — should make pharmacy-facing contract terms easier to audit against what the PBM is actually doing with manufacturers and plans.
A Worked Example: Spread Pricing vs. Cost-Plus
The reform is easiest to evaluate with real numbers, so here's a simplified version of the math a pharmacy owner should run before deciding whether to switch contracts.
Say a generic maintenance drug costs your pharmacy $22 per fill from your wholesaler.
- Under a spread-pricing contract: Caremark reimburses you at a rate tied to a benchmark list price that neither you nor the patient can easily verify. On a good month, that might net you $28 — a $6 margin. On a bad month, after a retroactive DIR-style fee is assessed against that same fill, your realized payment drops to $19 — a $3 loss you often don't find out about until weeks later, buried in a remittance adjustment file.
- Under cost-plus reimbursement: you're paid $22 (your actual acquisition cost) plus a fixed, disclosed dispensing fee — say $10.50. Every fill nets the same $10.50, with no retroactive surprise.
The cost-plus number might be lower than your best month under spread pricing, but it's also higher than your worst month, and — critically — it's the number you can actually put in a forecast. Run this comparison across your actual fill mix for the past 12 months, not a single drug, before deciding: pull your reimbursement detail report, bucket fills by therapeutic class, and compare total realized margin (after DIR adjustments) against what a flat acquisition-cost-plus-fee model would have paid on the same volume. Most independent pharmacy associations, including state-level NCPA affiliates, now offer template spreadsheets for exactly this comparison.
How This Compares to the ESI Settlement
Caremark is the second PBM the FTC has brought to a consent order over the same core insulin-pricing conduct, following its February 2026 settlement with Express Scripts (ESI). The Commission's underlying lawsuit named three PBMs — Caremark, ESI, and Optum — as having used similar rebating practices to inflate list prices; the case against Optum has been withdrawn from adjudication while the agency considers a proposed consent agreement of its own; a third settlement, on similar terms, may follow.
For a pharmacy that contracts with more than one of these PBMs — common for practices serving patients across multiple insurance networks — that pattern matters operationally. It means the accounting distinction between "reimbursement models" isn't going away with one contract renewal; it's likely to become a standing feature of how you reconcile revenue across payers. A pharmacy that builds the habit now — tracking reimbursement by PBM and by model (spread vs. cost-plus) as separate, comparable line items — will be ready to evaluate an Optum settlement on the same terms when it lands, instead of starting the analysis from scratch.
What to Actually Do With This as a Pharmacy Owner
None of these reforms roll out automatically to your benefit — you have to evaluate and, in most cases, opt in.
Model the cost-plus option against your current contract before switching. Cost-plus reimbursement trades upside for predictability. If you're currently profitable on a mix of high-margin generics under your spread-pricing contract, a flat acquisition-cost-plus-fee model might reduce total margin even as it removes the below-cost outliers. Run the numbers per drug class, not just in aggregate — a model that's a wash on your top 20 NDCs by volume can still be a net win if it eliminates your worst below-cost fills entirely.
Separate "gross reimbursement" from "true margin" in your records. If you've been booking prescription revenue at the reimbursement rate without tracking DIR-style post-sale adjustments as a distinct line, now is a good time to start. A cost-plus contract gives you a clean number to reconcile against; you'll want your books to actually reflect that cleanliness rather than folding retroactive clawbacks into whatever period they happen to land in.
Don't assume the reform applies automatically — read your renewal. The settlement requires Caremark to offer the cost-plus option and the point-of-sale rebate structure; it doesn't force every existing contract to convert. Flag your next contract renewal date and make sure the new options are actually on the table when it comes up.
Watch for hub pharmacy retaliation risk disappearing. If you've avoided referring patients to hub services out of concern about network standing, the independent-monitor protection is a change worth revisiting with your pharmacy's counsel or state pharmacy association.
The Bookkeeping Lesson Underneath the Headline
Whatever you decide about the reimbursement model itself, this settlement is a reminder of a broader problem independent pharmacies (and plenty of other small businesses working with opaque intermediaries) run into: when your revenue formula isn't transparent, your books can't be either. A ledger is only as trustworthy as the inputs feeding it, and "reimbursement rate TBD, subject to retroactive adjustment" is a hard thing to account for cleanly.
That's true well beyond pharmacy — any business that deals with delayed rebates, clawbacks, or fee structures it doesn't fully control (marketplace sellers, ad-network publishers, franchisees) benefits from separating "cash received" from "revenue recognized" and keeping an explicit, auditable trail of every adjustment rather than netting things down silently.
Keep Your Reimbursement Data as Clean as Your Ledger
If the Caremark settlement has you rethinking how you track PBM reimbursements, clawbacks, and dispensing-fee revenue, it's a good moment to also rethink how those numbers land in your books. Beancount.io offers plain-text, version-controlled accounting where every adjustment — a rebate pass-through, a retroactive DIR fee, a switch to cost-plus pricing — is a discrete, auditable entry instead of a black box. Get started for free and see how developers and finance-minded pharmacy owners are moving away from opaque spreadsheets toward accounting they can actually query and trust.